Healthcare Business Update: Merck Cancer Med Safe, Roche May Try Again
A massive evaluation found Merck & Co.’s (NYSE:MRK) Gardasil vaccine for preventing cervical cancer to be safe from the short-term effects of the drug. This was the second time in the past year that Gardasil was found to cause no immediate side effects, although worries still exist regarding the long-term impact. Meanwhile, the vaccine brought $1.2 billion in revenues in 2011.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Shares of ArQule (NASDAQ:ARQL) plunge 56 percent the day after the discontinuation of its Phase 3 Marquee (c-Met inhibitor ARQ 197) trial. A spokesperson said that “We are disappointed that the MARQUEE trial did not provide statistically significant results.”
The Times has reported that Roche (RHHBY.PK) might make another offer for Illumina (NASDAQ:ILMN), as shares of the latter move up. Illumina has already turned down $60 per share, and a previous Roche offer of $51 back in April.
Don’t Miss: What’s Next for Pfizer?